Introduction: The neuroendocrine histamine-secreting cell of the gastric fundus, the enterochromaffin-like cell, is the principal regulator of parietal cell acid secretion. We have proposed that histamine may regulate its own synthesis and release via an autocrine mechanism. The purpose of this study was to evaluate the role of the histamine receptor subtypes H1, H2 and H3 in the regulation of this phenomenon.
INTRODUCTION
Histamine is present in the stomach in higher concentrations than in any other body tissue. Its major source is the enterochromaffin-like (ECL)b cell of the oxyntic mucosa [1, 2] . bAbbreviations: ECL, Enterochromaffin-like; CCK, Cholecystokinin; TMPH, 2-([3-trimethyl]-diphenyl) histamine; EIA, Enzyme immuno-assay; PBS, Phosphate buffered saline; FCS, Fetal calf serum; ITS, Insulin-transferrin-sodium selenite; HDC, Histidine decarboxylase; R-MHA, R-a methyl histamine. 9 a critical role in gastric physiology [3] [4] [5] . Regulation of histamine secretion is complex and is primarily by gastrin activation of the ECL cell gastrin/CCK-B receptor, which stimulates both histamine synthesis and DNA synthesis [2] . Increased plasma gastrin levels result in ECL cell proliferation and increased histamine secretion [6] . The effects of elevated local histamine concentrations are unknown but of considerable relevance since histamine has protean biological effects including a substantial role in the genesis of inflammation and as a known mitogen in a number of cell systems [3] .
The specific physiological effects of histamine appear to be mediated by at least three subclasses of cell surface histamine receptors: H1 receptors were initially identified in the brain and noted to regulate the postsynaptic response to histamine [7] . The second subtype, the H2 receptor, and the identification of its relevance to gastric parietal cell secretion, revolutionized the therapy of acid-peptic disease [8] . Arrang et al. in 1983 demonstrated feed-back inhibition of histamine synthesis and release in histaminergic neurons in the brain through a third histamine receptor subtype [9] . The subsequent development of selective H3 receptor agonists and antagonists has led to the identification of this receptor subtype on a number of peripheral tissues including perivascular nerve terminals, the enteric ganglia of the ileum and the lung [10] [11] [12] [13] . In vivo, H3 receptor stimulation has been reported to inhibit gastrin, bombesin, 2-deoxyglucose and meal-stimulated acid secretion in cats and dogs [14] [15] [16] [17] . Additional studies have noted that H3 receptor stimulation inhibits histamine release from the rat stomach [18] , rabbit gastric gland [19] , rabbit gastric mucosal cells [20] and isolated rat ECL cells [2] .
The possibility that histamine could autoregulate its own synthesis and release was initially postulated in 1964 by Kahlson. He proposed that the labile histamine forming capacity observed in the gastric mucosa of cats, mice and frogs could be explained if there were to exist a feedback control of histamine forming capacity by the histamine content of the mucosa [21] . The subsequent identification of the ECL cell as a major source of mucosal histamine provided support for the erroneous suggestion that the ECL cell, via an H2-receptor, might negatively mediate its histamine secretory response to gastrin [22] . This postulate could not be adequately tested in an intact stomach or mucosal preparation.
The recent development of a preparation of pure, isolated ECL cells has allowed exploration of the regulatory mechanisms of acid secretion, histamine release and proliferation that have heretofore been impossible [2] . Since the ECL cell is the major physiologic site of histamine synthesis and secretion in the stomach, we have examined the proposal that its secretory function may be modulated by histamine autoreceptors. The purpose of this study was 
Cell isolation
Rat ECL cells were prepared by a modification of the method of Prinz [2] . The National Research Council's guide for the care and use of laboratory animals was followed.
For each condition studied, the stomachs from four animals (n = 1) were excised and everted to make mucosal-side-out sacs. Following a thorough rinse with PBS, pronase E was injected into the stomach sacs. The stomachs were then incubated in an oxygenated calcium-free medium containing 1 mM EDTA for 30 min, followed by a 10-min incubation in a calcium-respiration medium. The stomachs were then transferred back to calcium-free-EDTA medium for an additional 30- Gastrin-stimulated (10 nM) histamine secretion was inhibited in a similar fashion ( Figure  3 ). TMPH in a model of guinea pig ileal contraction was originally characterized with an EC50 of -1.5 x 10-7 M [23] . In addition, this molecule has been demonstrated to have a substantial cross reactivity with the H3 receptor subtype (EC50 _10-5 M) [23] . It is difficult to interpret the pharmacological effect of TMPH in our model because of the presence of substantial amounts of endogenous histamine which has a similar affinity (2 x 10-7 M) and efficacy (78 percent compared with TMPH) for the H1 receptor subtype. The high concentration required to inhibit secretion in our model suggests that this may be a non-pharmacological event or else represent cross-selectivity with other histamine receptor subtypes.
Terfenadine: The H1 receptor antagonist terfenadine (10-10 to 10-6 M) had no effect on basal or gastrin-stimulated (10 nM) histamine secretion.
In a separate set of studies (data not shown) we have shown that terfenadine at 1 nM inhibits gastrin-stimulated DNA synthesis and that this effect is completely reversed by TMPH in a dose dependent fashion with an estimated EC50 value of 10-9 M. It would thus seem more likely that the H1 receptor exhibits a proliferative rather than a secretory role. Histamine has been demonstrated to have a similar affinity and efficacy as these agents for the H2 receptor subtype [7] . The observation that the ECL cell does not respond to these agents suggests that under equivalent conditions, histamine has no direct effect on the ECL cell. Since the parietal cell expresses the H2 receptor subtype, it is possible that the ECL cell does not exhibit the H2 receptor. Histamine-3 receptor ligands ( Figure 4 ). The higher dosage of imetit was not used due to the concern of non-specific effects.
Thioperamide: The H3 receptor antagonist thioperamide (10-10 to 10-6 M) did not alter basal histamine secretion. However, pretreatment with thioperamide augmented a sub-maximal dose of gastrin-stimulated (1 nM) histamine secretion with a maximal effect (146 percent) at 10-8 M and an EC50 of 7 x 10-10 M ( Figure 5 ). This value is consistent with the reported affinity of thioperamide for the H3 receptor subtype (4 x 10-9 M) [10] .
Thioperamide then imetit, then gastrin: To determine the specificity of the effect of H3 receptor on gastrin-stimulated histamine secretion, cells were pretreated with H3 receptor antagonist thioperamide (10 nM) followed by the H3 receptor agonist imetit (10-10 to 10-6 M) and then stimulated with gastrin (1 nM). This abolished the previously observed imetit mediated inhibition of gastrin-stimulated histamine secretion (data not shown). Histamine has been demonstrated to have a substantially lower affinity (18-fold less) but a similar efficacy for the H3 receptor subtype compared with the specific H3 receptor agents [9] . The low concentrations of H3 agents required to alter histamine secretion support the presence of an H3 receptor on the ECL cell. It is probable that histamine, albeit at a higher concentration, has a similar effect. Pharmacological manipulation of the H3 receptor with highly specific agents, therefore, demonstrates unequivocally that receptor activation of the ECL cell results in inhibition of histamine release.
DISCUSSION
Although the role of histamine in normal physiology has been widely investigated, its biological relevance is incompletely understood. Nevertheless, compounds that selectively antagonize the actions of histamine at these specific cell surface receptors are of considerable clinical utility. Histamine has been determined to exert its complex physiologic and pathologic effects through interaction with at least three receptor subtypes (H1, H2 and H3) [7, 24] identified on numerous different cell systems including neural and gastrointestinal. Message transduction via the H1 receptor has been shown to involve alterations in calcium homeostasis and increased production of inositol phosphate, while H2 receptors are reported to act through elevation of cAMP [3] . The mode of action of H3 receptors is unknown but it is thought to be negatively coupled to phosphatidylinositol turnover [25] .
A role for the H1 receptor in the regulation of gastric histamine secretion is both unclear and controversial but has been suggested from the results of experiments with anesthetised dogs with gastric fistulas. In these experiments, infusion of an H1-receptor agonist (2', 2-pyridyl ethylamine) had no effect on dimaprit stimulated acid secretion [26] . However, infusion of the specific receptor antagonist, hydroxyzine dihydrochloride, enhanced both histamine and dimaprit stimulated gastric acid secretion. Removal of an autoinhibitory effect of histamine on histamine secretion from the ECL cell by an H1 receptor antagonist might explain these data but the precise interpretation of such studies in intact animals has been difficult. The presence of H1 receptors in the gastric mucosa has been suggested by binding studies. In preliminary studies, [3H]Mepyramine binding in gastric tissue samples from the African rodent Praomys natalensis indicated low levels of H1-receptors in both antrum and fundus, -15 fmol/mg protein [27] . The further possibility that the receptor sites were present on ECL cells was supported by an increased degree of binding in ECL cells isolated from fundic ECL carcinoid tumors (Schwartz and Modlin, unpublished data).
In order to evaluate the role of the HI receptor directly, we used the agents TMPH and terfenadine. TMPH is a 3-trifluoromethyl derivative of histamine, which is a specific H1 receptor agonist, and has been reported to be similarly potent to histamine in the guinea pig ileum assay [23] . Terfenadine is a selective, slow-associating H1 receptor antagonist, which forms a stable complex and has been demonstrated to have a IC50 of 0.2 uM for ileal H1 receptors [28] . In an isolated purified preparation of ECL cells, the H1 receptor agonist, TMPH (at high dosage), significantly inhibited both basal and a maximal dose of gastrin-stimulated (10 nM) histamine secretion with IC50 > 0.5 uM. However, the H1 receptor antagonist, terfenadine, had no effect on either basal or gastrin driven histamine release. Although these results suggest that ECL cell histamine secretion can be modulated by the H1 receptor subtype, the high concentrations required are of concern. In addition, since the H1 receptor clearly modulates proliferation both in vivo and in vitro, it seems more likely that the observed effects reflect a degree of non-selectivity or crossreactivity with the H3 receptor subtype generated by high dosages of a pharmacological compound.
The histamine-2 receptor has been identified on the parietal cell, and pharmacological blockade has proved efficacious in the treatment of patients with acid related disorders. The presence of an H2 receptor and evidence for an H2 mediated feed-back inhibition on ECL cell histamine release was initially proposed in 1978 [22] . Histamine has been demonstrated both to inhibit HDC activity in vivo and to decrease the half-life of the enzyme [22] . Intravenous infusion of histamine in rats treated with the H2 receptor blocker, metiamide, resulted in a significantly reduced suppression of HDC activity and in addition, pentagastrin-induced HDC activity in the fundic mucosa was significantly increased. The effect of these agents on histamine secretion was not determined. Based on this information, Hikanson postulated that H2 receptor blockade might be mediated at the level of the ECL cell rather than the parietal cell. Our studies, utilizing a purified population of ECL cells, demonstrated that the specific H2 receptor agonist, dimaprit, had no effect on either basal or gastrin-stimulated histamine secretion. Similarly, the specific H2 antagonists, cimetidine and loxtidine, had no effect on histamine secretion. In separate studies, we have reported that neither H2 receptor activation nor blockade altered basal or gastrin-stimulated histamine secretion or DNA synthesis [27] , suggesting that there is no evidence for a role of the H2 receptor subtype in the regulation of the ECL cell.
The histamine-3 receptor was initially described in the brain, where it inhibits histamine synthesis and release [29] . H3 receptors were subsequently identified in the enteric ganglia of the gastrointestinal tract, and evidence provided to support a role in the modulation of cholinergic neurotransmission [30] . More recently, it has been reported that this class of histamine receptor subtype is involved in the control of gastric acid secretion. Evidence for the existence of a gastric H3 receptor was initially derived from in vivo studies utilizing fistula cats [14, 31] . Acid secretion stimulated by meal or pentagastrin was potently and dose-dependently inhibited by the specific H3 agonist, R-MHA. This activation could be reversed by the specific antagonist, thioperamide. Similar findings were observed in a denervated Heidenhain pouch, suggesting that extrinsic cholinergic vagal nerves were not involved in this process. In addition, in the isolated rat stomach, R-MHA inhibited both basal and gastrin-stimulated vascular histamine release in a ranitidineinsensitive manner [18] , suggesting direct modulation of histamine receptors on histamine secreting cells. Indeed to date, no evidence exists for the presence of H3 receptors on the parietal cell. Furthermore, histamine inhibited HDC activity in isolated rabbit mucosal cell preparations can be augmented by R-MHA and reversed by thioperamide [20] . Histamine thus appears to inhibit its own synthesis via H3 autoreceptors within the gastric mucosa. Evidence for the functional presence of an H3 receptor in isolated rat ECL cells was reported by Prinz et al. [2] . Their results indicated a specific inhibition of maximal CCK-8 (10-8 M) stimulated histamine release by R-MHA with a maximum effect at 10-6 M. In addition, the effects of a sub-maximal dose (10-10 M) of CCK-8 could be augmented by thioperamide maximally at 10-8 M. In order to evaluate the role of the H3 receptor directly, we used the agents imetit and thioperamide. Imetit is a potent, selective H3 receptor agonist, which is equipotent to R-MHA. Both agents exhibit -3x the inhibitory effect of histamine for [3H]-histamine release from rat cortical slices [29] . Thioperamide is a competitive H3 receptor antagonist with little cross-reactivity for either the H1 or H2 receptors [10] . Using similarly isolated cells that were allowed to recover following overnight culture, we have demonstrated that imetit specifically inhibits a submaximal dose of gastrin (10-9 M) [27] , it is probable that the H3 receptor functions in different affinity states which variously alter DNA synthesis or modify histamine secretion. Both the gastrin/CCK-B receptor and the CCK-A receptor are known to exhibit such phenomena [32] .
In the ECL, cell the EC50 for gastrin mediated ECL cell DNA synthesis is an order of magnitude less than for histamine secretion [33, 34] . Both high and low affinity states for H3 receptors have been demonstrated using radiolabelling of cerebral membranes [29] . High affinity binding has been proposed to modulate HDC activity, while low affinity binding is thought to regulate histamine secretion. Low levels of basal histamine release are postulated to down-regulate histamine synthesis, while high concentrations of histamine consequent upon stimulated secretion inhibit histamine release [20] . Our results demonstrate that H3 receptor activation results in substantial inhibition of histamine release. It is probable that histamine released by gastrin would remain in very close proximity to the ECL cell and result in accumulation of histamine at a high local concentration. Under these circumstances, it is feasible that histamine induces a local feedback inhibitory effect via the H3 receptor and thus downregulates the initial systemic hormonal signal. It is, therefore, possible that in the gastric mucosa a component of the physiologic function of histamine receptor subtypes may be to exert tonic inhibition of acid secretion via regulation of ECL cell histamine secretion and synthesis.
The utility of pharmacological compounds to define specific receptor subtype activity is limited by the specificity of such agents. Thus, it cannot be excluded that the observed effects of TMPH at high dosage reflect an effect on the H3 receptor. Nevertheless, the effect of the various histamine receptor subtype probes clearly indicates a role for the histamine receptor subtype 3 in the modulation of histamine secretion. The validity of this proposal is further supported by the autoradiographic demonstration of the H3 receptor on the isolated ECL cell [27] . Given the critical position of the ECL cell in the regulation of acid secretion, the existence of a histamine-activated autoregulatory secretory mechanism is of considerable physiological and possibly clinical relevance.
